40483-41-8Relevant academic research and scientific papers
Synthesis of trifluoromethylated 2-benzoyl- and 2-aminoimidazoles from ring rearrangement of 1,2,4-oxadiazole derivatives
Palumbo Piccionello, Antonio,Pace, Andrea,Buscemi, Silvestre,Vivona, Nicolò,Pani, Marcella
, p. 4004 - 4010 (2008/09/20)
Fluoroalkylated 2-ylamino-imidazoles have been synthesized by reaction of 3-amino-5-phenyl-1,2,4-oxadiazole with fluorinated β-dicarbonyl compounds and subsequent base-induced Boulton-Katritzky Rearrangement (BKR) of the isolated β-enaminocarbonyl interme
Heterocyclic Rearrangements: Rearrangement of N-(1,2,4-Oxadiazol-3-yl)-β-enamino Ketones into Pyrimidine N-Oxides
Vivona, Nicolo,Buscemi, Silvestre,Frenna, Vincenzo,Ruccia, Michele
, p. 17 - 20 (2007/10/02)
The behaviour of N-(5-R-1,2,4-oxadiazol-3-yl)-β-enamino ketones towards rearrangement has been investigated.In the presence of anionic reagents in ethanol solution, they rearrange to pyrimidine N-oxides.The synthesis and hydrolytic ring opening of a oxadiazolopyrimidinium system is also reported.
Potential Radiosensitizing Agents III: 2-Nitro-4-Acetylimidazole Analogs
Seghal, Raj K.,Agrawal, Krishna C.
, p. 1203 - 1206 (2007/10/02)
New analogs of 2-nitroimidazole have been synthesized in an effort to minimize the toxicity and increase selective sensitization of hypoxic mammalian cells toward lethal effects of ionizing radiation. 2-Nitro-4(5)-acetyl-5(4)-methylimidazole was synthesized from the corresponding 2-amino analog and then reacted with oxiranes to produce the corresponding 1-substituted 2-propanol and 3-methoxy-2-propanol derivatives.The biological results of radiosensitizing activity of these agents against Chinese hamster cells (V-79) indicated that the 3-methoxy-2-propanol derivative was a more effective radiosensitizer than misonidazole in vitro.Evaluation of the acute toxicity of these agents as determined by LD50 demonstrated no significant difference between these agents and misonidazole suggesting that the 3-methoxy-2-propanol analog may posess a therapeutic advantage over misonidazole.
